This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology
Journal of Hematology & Oncology Open Access 02 March 2018
-
Fighting against hematological malignancy in China: from unique system to global impact
Science China Life Sciences Open Access 14 November 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041–6051.
National Comprehensive Cancer Network clinical practice guidelines in oncology: chronic myelogenous leukemia version 2 2011. http://www.nccn.org/NCCN Guidelinesâ„¢ & Clinical Resources/(accessed 20 June 2011).
Vardiman JW, Harris NL, Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302.
Huang XJ, Xu LP, Liu KY, Liu DH, Chen H, Liu YR et al. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for subjects with chronic myeloid leukemia. Biol Blood Marrow Transplant 2010; 17: 649–656.
Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for subjects with chronic myelogenous leukemia in the accelerated phase. Blood 2011; 117: 3032–3040.
Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A et al. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood 2012; 119: 5963–5971.
Klein JP, Zhang MJ . Statistical challenges in comparing chemotherapy and bone marrow transplantation as a treatment for leukemia. In: Jewell, Kimber, Lee, Whitmore (eds). Lifetime data: models in reliability and survival analysis. Kluwer Academic Publishers: Boston, MA, 1996; pp 175–185.
Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054–1061.
Deininger M, O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114, Abstract # 1126.
Pavlu J, Szydlo RM, Goldman JM, Apperley JF . Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 2011; 117: 755–763.
Radich J . Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin Hematol 2010; 47: 354–361.
National Marrow Donor ProgramDisease and transplant outcome data, NMDP-facilitated transplant outcomes. National Marrow Donor Program, 2004. Available from URL http://www.marrow.org/MEDICAL/diseaseoutcomedata.html(accessed 20 June 2011).
Robin M, Guardiola P, Devergie A, Yeshurun M, Shapiro S, Esperou H et al. A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia 2005; 19: 1613–1620.
de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358–3363.
Jabbour E, Kantarjian H, O'Brien S, Shan J, Quintas-Cardama A, Faderl S et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011; 118: 4541–4546.
Acknowledgements
This work was supported by the Key Program of National Natural Science Foundation of China (grant no. 81230013), the Beijing Municipal Science and Technology Program (grant no. Z111107067311070) and Leading Program of Clinical Faculty accredited by the Ministry of Health of China (2010–2012). Robert Peter Gale kindly acknowledges support from the NIHR Biomedical Research Centre funding scheme. Professors John Goldman, Hagop Kantarjian and Rudiger Hehlmann kindly reviewed the typescript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
RPG is a part-time employee of Celgene Corporation, Summit, NJ, USA. The remaining authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Jiang, Q., Xu, LP., Liu, DH. et al. Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia. Leukemia 27, 2410–2413 (2013). https://doi.org/10.1038/leu.2013.159
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.159
This article is cited by
-
Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia
Journal of Cancer Research and Clinical Oncology (2022)
-
The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology
Journal of Hematology & Oncology (2018)
-
Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia
Annals of Hematology (2017)
-
Fighting against hematological malignancy in China: from unique system to global impact
Science China Life Sciences (2015)
-
The role of hematopoietic stem cell transplantation in chronic myeloid leukemia
Annals of Hematology (2015)